Background ABP 501, a U.S.A. Food and Drug Administration-and European Medicines Agency-approved biosimilar, is highly similar to adalimumab in structure, function and pharmacokinetics. Objectives To demonstrate similarity in efficacy, safety and immunogenicity of ABP 501 vs. adalimumab for moderate-to-severe plaque psoriasis (clinical trial: NCT01970488). Methods Patients were randomized (1 : 1) to receive ABP 501 or adalimumab 40 mg every 2 weeks for 16 weeks. At week 16, patients with ≥ 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) score were eligible to continue to week 52. Patients receiving ABP 501 continued; adalimumab patients were rerandomized (1 : 1) to continue adalimumab or undergo a single transition to ABP 501. Key efficacy assessments included percentage PASI improvement from baseline, PASI responders and mean change in affected body surface area from baseline to weeks 16, 32 and 50. Safety was monitored via adverse events (AEs) and antidrug antibodies (ADAs) were assessed. Results A total of 308 patients were rerandomized at week 16 (ABP 501/ABP 501, n = 152; adalimumab/adalimumab, n = 79; adalimumab/ABP 501, n = 77). PASI percentage improvements from baseline were similar across groups for weeks 16, 32 and 50 (range: 85Á8-88Á2%), with no significant differences detected across groups in percentages of PASI 50, 75, 90 and 100 responders. Changes from baseline in percentage body surface area affected were similar across groups and time points. No new safety signals were detected. AEs were balanced between groups. Percentages of patients with binding and neutralizing ADAs were similar across treatments.
Conclusions ABP 501 and adalimumab have similar clinical efficacy, safety and immunogenicity profiles over 52 weeks, including after single transition, in this patient population.
What's already known about this topic?
• Biosimilars can offer therapeutic alternatives for patients in need and are currently being developed for numerous diseases, including moderate-to-severe plaque psoriasis.
• ABP 501 is a U.S. Food and Drug Administration-and European Medicines Agency-approved biosimilar to adalimumab and has been shown to be highly similar to adalimumab in structural, functional and pharmacokinetic evaluations.
What does this study add?
• The current study demonstrates that ABP 501 and adalimumab are highly similar in clinical efficacy, safety and immunogenicity, including after single transition from adalimumab to ABP 501 treatment, in patients with stable moderate-to-severe plaque psoriasis.
Biosimilars, biological products that are similar to already licensed reference products, are currently being developed for a range of diseases. 1 These have the potential to provide additional therapeutic options for patients in need of treatment with biologics. Numerous complexities and proprietary processes are involved in the development of biological proteins. Thus, guidelines have been developed by regulatory agencies on how to demonstrate that a proposed biosimilar is highly similar to the reference product and that there are no clinically meaningful differences in safety, purity and potency between the proposed biosimilar and reference product. 1,2 Guidelines on biosimilars also indicate that clinical trials should include sensitive populations and appropriate end points to enable detection of any clinically meaningful differences across treatments, if such differences exist. 3, 4 Similarity to the reference drug must be shown via a stepwise, totality of evidence approach for structure, function, physiochemical, pharmacokinetic/pharmacodynamic, clinical efficacy and clinical safety. 1, 2, 4 Long-term trials are critical to demonstrate that biosimilars are safe and effective for patients who will receive maintenance treatment for lengthy durations. Studying a single transition from the reference product to the biosimilar is especially important to determine safety, immunogenicity and possible diminishing efficacy for patients who may transition treatments. The U.S. Food and Drug Administration (FDA) has recently approved the first U.S. monoclonal antibody biosimilar, Inflectra TM (infliximab-dyyb, Hospira, Lake Forest, IL, U.S.A.), for all of the reference product (Remicade â , Janssen Biotech, Inc., Horsham, PA, U.S.A.) indications, including psoriasis. 5, 6 This was followed by FDA approval of the biosimilar Erelzi TM (etanercept-szzs, Novartis Pharma AG, Stein, Switzerland) Canada, the biosimilar infliximab (Remsima) has been approved for rheumatological and dermatological indications.
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The ABP 501 biosimilar to adalimumab, a human IgG1 monoclonal antibody that binds to and inhibits tumour necrosis factor (TNF)-a, has been indicated by the FDA to treat moderately-to-severely active rheumatoid arthritis, moderately-to-severely active polyarticular juvenile idiopathic arthritis (≥ 4 years of age), active psoriatic arthritis, active ankylosing spondylitis, moderately-to-severely active adult Crohn's disease, moderately-to-severely active ulcerative colitis and moderate-to-severe chronic plaque psoriasis (patients who are candidates for systemic therapy or phototherapy). 8, 9 In addition to these, the EMA indications for ABP 501 will also include axial spondyloarthritis, uveitis, hidradenitis suppurativa, paediatric Crohn's disease (≥ 6 years of age), paediatric plaque psoriasis (≥ 4 years of age), paediatric enthesitisrelated arthritis (≥ 6 years of age) and polyarticular juvenile idiopathic arthritis (≥ 2 years of age). 12, 13 Long-term studies have shown that biologics, such as adalimumab, that inhibit cytokines (e.g. TNF-a) important in the immunopathogenesis of moderate-to-severe psoriasis, are safe and effective. [16] [17] [18] [19] [20] [21] Analytical and functional evaluations have demonstrated that ABP 501 and adalimumab are highly similar in their structural and functional properties, as well as biological activity. 22, 23 A phase I, single-dose study of ABP 501 in healthy adults demonstrated similar pharmacokinetics to that of adalimumab. 24 To establish similarity between ABP 501 and adalimumab in clinical efficacy, safety and immunogenicity, two phase III studies were conducted: one in patients with moderate-to-severe rheumatoid arthritis (NCT01970475) and the other in patients with moderate-to-severe plaque psoriasis (NCT01970488). 25, 26 This phase III, randomized, double-blind, 52-week study was designed to demonstrate clinical similarity in the efficacy, safety and immunogenicity of ABP 501 compared with adalimumab for the treatment of patients with moderate-to-severe plaque psoriasis. Results for the primary efficacy and safety end points at week 16 have previously been reported. 26 Here we report the 52-week efficacy and safety results from this study including data from patients who underwent a single transition from adalimumab to ABP 501.
Patients and methods

Study population
Full details on the methodology of this study have been previously reported. 26 Briefly, patients eligible for enrolment were 18-75 years of age with stable moderate-to-severe plaque psoriasis for ≥ 6 months, were candidates for systemic therapy or phototherapy, and had inadequately responded to or were unable to tolerate/receive at least one conventional systemic therapy. Patients were required to have disease involvement of ≥ 10% of body surface area (BSA), a Psoriasis Area and Severity Index (PASI) score ≥ 12 (PASI score range: 0-72; higher scores indicate more severe disease) 27 and a static Physician's Global Assessment (sPGA) of at least moderate severity (sPGA range: 0-5; from clear, 0 to very severe, 5). 28 Patients who had previously used adalimumab, a biosimilar of adalimumab, or at least two biologics for psoriasis were excluded. This study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. The study protocol was approved by the institutional review board or independent ethics committee at each participating site and the study was conducted in adherence with all local regulatory requirements including those for data protection. Written informed consent was obtained from each patient prior to enrolment in the study and before initiation of any study-related procedure.
Study design
This was a randomized, double-blind, multicentre, active-controlled, phase III trial, with a 4-week screening period, after which eligible patients were randomized (1 : 1) to receive treatment with ABP 501 or adalimumab for 16 weeks (Fig. 1) . ABP 501 and adalimumab were administered at an initial loading dose of 80 mg subcutaneously on week 1/day 1, followed by 40 mg subcutaneously every other week (starting at week 2) for 16 weeks. At week 16, all patients with ≥ 50% improvement from baseline in PASI score (PASI 50) were eligible to remain in the study and were rerandomized to continue until 52 weeks. Patients who were initially randomized to receive ABP 501 continued treatment, and patients initially randomized to receive adalimumab were rerandomized in a 1 : 1 ratio to either continue adalimumab treatment or undergo a single transition to treatment with ABP 501. All patients continued assigned treatment every 2 weeks until week 48, when the last dose of the investigational product was administered, followed by a 4-week safety follow-up period. The final efficacy assessments were conducted at week 50 and the end-of-study visit was at week 52. The study was conducted in six countries and 49 centres across Europe, North America and Australia.
Study assessments
The previously reported primary efficacy end point for this study was the per cent improvement in PASI score from baseline to week 16. 26 Key efficacy assessments reported here include PASI 50, PASI 75, PASI 90 and PASI 100 responses, sPGA response of clear (0) or almost clear (1) and mean change in affected BSA from baseline at weeks 16, 32 and 50, after rerandomization. Not all patients who completed week 16 were rerandomized, thus, the safety analyses focused on events occurring only in the rerandomized population from week 16 to week 52. Safety was assessed via monitoring for treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events (AEs) of interest (e.g. infections, malignancies, hypersensitivity) based on Standard Medical Dictionary for Regulatory Activities queries, laboratory data (weeks 16, 32, 44 and 52), vital signs (every 2 weeks) and immunogenicity (weeks 16, 20, 32 and 52) after rerandomization.
The incidence of antidrug antibodies (ADAs) were assessed using a highly sensitive and drug-tolerant assay based on the Meso Scale Discovery Electrochemiluminescent platform. 29 A two-tiered approach was conducted simultaneously to detect all ADAs that bind to the biologic drug (binding antibodies) and to confirm the specificity of the binding antibodies. 30 The assay sensitivity for ADAs was approximately 0Á02 lg mL À1 in the presence of 25 lg mL À1 drug using an affinity-purified rabbit positive control antibody diluted in pooled human serum. For the specificity assay, samples that showed a signalto-noise ratio reduction in the presence of excess soluble drug were reported as positive. 31, 32 Samples positive for binding ADAs were tested for neutralizing antibodies, which interfere with the therapeutic activity of the biologic drug. This allowed for detection of higher ADA rates as compared with those seen with Humira â .
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Statistical analysis
Previously reported efficacy data from baseline to week 16 were analysed using the full analysis set, which included all patients initially randomized in the study, and was the only inferential analysis. 26 Randomization, conducted by an independent statistician, was computer generated and was stratified by geographic region and prior biologic use. ABP 501 and adalimumab were provided in prefilled, indistinguishable syringes, dispensed by the Interactive Voice and Response System; all patients and personnel involved with study conduct and interpretation were masked to the patient's treatment assignment. The rerandomized analysis set, which included patients who were PASI 50 responders and were rerandomized at week 16, was used to analyse efficacy data descriptively collected through to week 50. The safety analysis set included all randomized patients who received at least one dose of the investigational product, and the immunogenicity analysis included patients in the safety analysis who had at least one evaluable antibody test result. Descriptive statistics were provided for efficacy, safety and immunogenicity data after week 16 (after rerandomization) through to week 52 based on initial/rerandomization treatment. PASI per cent improvement from baseline, PASI 50, PASI 75, PASI 90 and PASI 100 responses, sPGA summaries by frequency and percentage of participants, and psoriasis BSA scores at weeks 16, 32 and 50 were summarized by initial/ rerandomization treatment using the rerandomized analysis set. Equivalence was evaluated descriptively at weeks 16, 32 and 50 by providing the two-sided 95% confidence interval (CI) of the differences between the ABP 501/ABP 501 and adalimumab/adalimumab groups as well as between the adalimumab/ABP 501 and adalimumab/adalimumab groups using the rerandomized analysis set as observed. The 95% CIs of the differences were estimated using an ANCOVA model that contained all three treatment combinations and adjusted for baseline scores and stratification factors (geographic region and prior biologic use for psoriasis) as covariates.
Results
Patient demographics and characteristics
A total of 350 patients were enrolled, equally randomized to each group, and included in the full analysis set up to week 16 adalimumab, n = 173) who received at least one dose of investigational product. 26 A total of 326 (93Á1%) patients completed the trial through to week 16 and 308 (88Á0%) of those patients, who all achieved the predefined criteria of PASI 50, were rerandomized to continue through to week 52. Of the 42 patients (ABP 501, n = 23; adalimumab, n = 19) who were not rerandomized, most (n = 21) were a result of protocol-specified criteria (n = 17 because they did not attain a PASI 50 response) followed by AEs (n = 11). Both the number of patients rerandomized and reasons for not continuing the trial were balanced between treatment groups. Baseline characteristics for the rerandomized populations were balanced between treatment groups (Table 1 ). A total of 272 patients completed the study and 36 patients discontinued after rerandomization (Table S1 ; see Supporting Information).
Efficacy
Psoriasis Area and Severity Index improvement from baseline
Patients in the rerandomized groups achieved mean PASI per cent improvements from baseline to week 16 of 86Á6% (ABP 501/ABP 501), 88Á0% (adalimumab/adalimumab) and 88Á2%
(adalimumab/ABP 501) and from baseline to week 32 of 87Á6% (ABP 501/ABP 501), 88Á2% (adalimumab/adalimumab) and 87Á0% (adalimumab/ABP 501) (Fig. 2) . Similarly, at week 50, rerandomized patients reached mean PASI per cent improvements from baseline of 87Á2% (ABP 501/ ABP 501), 88Á1% (adalimumab/adalimumab) and 85Á8% (adalimumab/ABP 501).
Psoriasis Area and Severity Index responders
Of the rerandomized population, no significant differences between the ABP 501/ABP 501 or adalimumab/ABP 501 groups vs. the adalimumab/adalimumab group were detected in percentages of PASI 50, PASI 75, PASI 90 and PASI 100 responders for weeks 16, 32 and 50 (Fig. 3) . The percentages of patients who showed a PASI response remained similar from week 16 to week 50 for PASI 50 and 75, and the percentages of responders increased across these weeks for PASI 90 and 100.
Static Physician's Global Assessment responders
For the rerandomized patients, a positive response was seen in 66Á4% of ABP 501/ABP 501 patients, 73.4% of adalimumab/ Systemic excludes biological therapyÁ adalimumab patients, and 67.5% of adalimumab/ABP 501 patients at week 16 (Fig. 4) . Similar sPGA positive responses were observed at weeks 32 and 50 with treatment differences for both time points that ranged from À4Á2% to À9Á6% for the ABP 501/ABP 501 or adalimumab/ABP 501 groups vs. the adalimumab/adalimumab group.
Changes from baseline in affected body surface area
Similarly, the rerandomized population showed changes from baseline in per cent BSA affected of À19Á3%, À24Á2% and À23Á5% for the ABP 501/ABP 501, adalimumab/adalimumab and adalimumab/ABP 501 groups, respectively. Week 32 and 50 BSA results were similar to those at week 16 and percentages for each group at all time points were comparable (Fig. 5) .
Safety
Overall safety week 16 to week 52
Among the rerandomized population, similar percentages of patients experienced at least one TEAE from week 16 to 52 ( Table 2 ) (Fig. 6 ). Imbalances in TEAEs ≥ 5% across any of the three treatment groups included nasopharyngitis, headache, diarrhoea and back pain. The only TEAE that led to discontinuation by more than one patient was psoriasis (only ABP 501/ABP 501 group, n = 2) and there was no trend in the type of TEAEs that led to discontinuation. A total of 14 SAEs were reported in 12 patients with the lowest percentages occurring in the ABP 501/ABP 501 group (Table S2 ; see Supporting Information). Changes from baseline in laboratory values to end of study, including haematology and serum chemistry, were similar across all treatment groups and no clinically meaningful changes in vital signs were observed over the course of the study.
Adverse events of interest
AEs of interest that were reported from week 16 to 52 are presented in Table 3 and Figure 6 . The most common infections (ABP 501/ABP 501, adalimumab/adalimumab, adalimumab/ABP 501) were nasopharyngitis (16Á4%, 17.7%, 23.4%, respectively) and upper respiratory tract infection (5Á9%, 7.6%, 9.1%, respectively). From week 16 to 52, one event of squamous cell carcinoma of the skin was reported in the ABP 501/ABP 501 group. No clinically meaningful differences were observed across groups for hypersensitivities as the overall number reported was low. Hypersensitivities that occurred in more than two patients in any treatment group were contact dermatitis (ABP 501/ABP 501, n = 4; all unrelated to treatment), rash (ABP 501/ABP 501, n = 3) and urticaria (adalimumab/ABP 501, n = 2). Haematological reactions occurred in two patients (two events each): one patient in the adalimumab/adalimumab group experienced decreased neutrophil and total white blood cell counts, from which they recovered; one patient in the adalimumab/ABP 501 group reported leucopenia and neutropenia, both of which did not resolve, and did not lead to study discontinuation or change in dosage. Changes in liver enzymes from week 16 to 52 occurred in 13 patients with higher proportions of patients in the ABP 501/ABP 501 group who showed increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT), compared with the other two groups. All of these increases in the ABP 501/ABP 501 group were grade 1 or 2 in severity and were resolved by study end, except one occurrence of elevated GGT that remained unresolved. One ABP 501/ABP 501 patient experienced increases in liver enzymes (ALT 6 9 upper limit of normal; AST 3 9 upper limit of normal). Treatment was discontinued and the event was reported as resolved. A total of five patients experienced injection-site reactions from week 16 to 52, the majority of which were injection-site pain. There were no deaths during the study period and no cases of demyelinating disease, heart failure or lupus-like syndromes throughout the study. No cases of reactivation of latent tuberculosis were reported among the rerandomized population.
Immunogenicity
From baseline to study end, among only the patients who were rerandomized, pre-existing binding antibodies were reported predose in one patient for each of the three groups and no pre-existing neutralizing antibodies were reported. A total of 72Á3% (251 of 347) of rerandomized patients tested positive for binding ADAs and 21Á9% (76 of 347) for neutralizing antibodies over the course of the study. The percentages of patients who developed ADAs and neutralizing antibodies were generally similar across groups over the entire 52 weeks of treatment (Fig. 7a) . In order to have a clear understanding of the development of new ADAs after the single transition, analysis was conducted for patients who were binding ADA negative or had no result through to week 16 of the study. The percentages of these patients who developed ADAs were also similar across groups with no neutralizing antibodies detected for all (Fig. 7b) .
Discussion
Data from this long-term, phase III, clinical trial demonstrate that ABP 501 is similar in clinical efficacy and safety to the adalimumab reference product. Patients in both the ABP 501 and adalimumab groups had statistically similar results for the primary end point of per cent improvement in PASI at week 16, indicating that these treatments are equivalent in efficacy for patients with moderate-to-severe psoriasis. 26 Following a single transition from adalimumab to ABP 501, efficacy measures such as per cent improvement in PASI, PASI 50/75/90/ 100 response results, sPGA and BSA affected were similar across groups from the transition point (week 16) to the end of the study. Throughout the 52-week study, similar percentages of patients in each group achieved consistently similar clinical efficacy. Patients who transitioned from adalimumab to ABP 501 at week 16 showed similar efficacy in all of these measures for the remainder of the study. These data indicate that ABP 501 and adalimumab are similar treatments, in terms of efficacy, for patients with moderate-to-severe psoriasis. Monitoring of immunogenicity is critical as ADAs can lead to decreased efficacy. As previously published, the electrochemiluminescent bridging assay used to detect ADAs in this study is highly sensitive and drug tolerant, 24 and may be reflected in the higher incidences of ADAs observed in this study compared with those observed in previous adalimumab trials. 9, 29 The frequencies of developing ADAs for patients receiving ABP 501 and adalimumab, including those patients who transitioned from adalimumab to ABP 501, were balanced over the course of the study, as would be expected in a comparative biosimilar evaluation. Immunogenicity analysis was conducted for patients who were binding ADA negative or who had no result at rerandomization (week 16) to evaluate how single transition from ABP 501 to adalimumab affected development of new ADAs. Additionally, for the rerandomized population, geometric mean trough serum concentrations throughout the study were similar across groups indicating that exposure was similar between all treatment groups in this population (data on file). As previously demonstrated by Bartelds and colleagues 33 with adalimumab, the current immunogenicity results indicate that ADA development for both ABP 501 and adalimumab occur early in the course of treatment. Patients who did not achieve PASI 50 at week 16 were not rerandomized to continue to week 52. Thus, it is not possible to determine fully if treatment failure because of ADA development leads to high rates of treatment discontinuation over the long term as observed in the Bartelds et al. study.
However, in the current trial, similar percentages of patients discontinued across treatment groups among patients who were rerandomized at week 16 and treatment efficacy remained robust and similar across groups through to week 52. Overall, the data observed here further demonstrate that the immunogenicity profiles of both treatments, including a transition from adalimumab to ABP 501, were similar and long-term treatment efficacy were similarly maintained.
The safety results from this study were generally similar to those seen in the total population prior to rerandomization (from baseline to week 16). 26 Additionally, the most commonly observed adverse events for the rerandomized population from baseline to the end of the study were similar to those seen here from week 16 to the end of the study, with nasopharyngitis, upper respiratory tract infections and headache most commonly observed for both time periods. TNF-ainhibitors are generally well tolerated; however, there are increased risks for certain opportunistic infections, lupus-like syndrome and demyelinating diseases. 20, [34] [35] [36] In this study, only one patient experienced an infection that was grade 3 or higher (adalimumab/ABP 501, urinary tract infection) and no instances of lupus-like syndrome, demyelinating disease or death occurred. Changes from baseline in haematological reactions and liver enzyme elevations were similar between treatment groups. Patients with rheumatoid arthritis have increased risk for cardiovascular morbidity and mortality, with data suggesting the same for patients with psoriasis; however, treatment with TNF inhibitors have been shown to reduce these cardiovascular risks. 37 A clinical trial designed to assess the effects of adalimumab on lowering cardiovascular risk in patients with rheumatoid arthritis is currently ongoing (NCT01893996) and will provide more information on the effects of these treatments on cardiovascular morbidity and Unlike most small-molecule generic drugs, the biosimilar biological molecules are particularly difficult to develop as small differences in design and execution can have a potentially significant impact on the protein profile. Because slight modifications have the propensity to trigger immunogenicity or change the clinical profile of a biosimilar, stringent regulatory guidelines exist that require thorough characterization of the structure and function of biosimilars, ensuring that there are no clinically meaningful differences between the proposed biosimilar and reference product. 4 Comparative analytical, preclinical and clinical studies in sensitive populations that show similarity between the proposed biosimilar and reference product are required to obtain FDA and EMA approval for use. 2, 4 A limitation of the current study is the lack of an evaluation of a maintenance response after 52 weeks of treatment. The open-label extension of the adalimumab REVEAL study determined that efficacy was well maintained for over 3 years in patients who showed an initial PASI 75 response. 18 The rigorous requirements for showing overall similarity between a biosimilar and the reference product would indicate that longterm maintenance of efficacy for ABP 501 may be similar to that seen with adalimumab; however, this can only be determined following prolonged treatment with ABP 501 in moderate-to-severe psoriasis patients. Comprehensive analytical assessment of ABP 501 compared with adalimumab has shown that the two molecules are highly similar in physicochemical properties 22 and biological activity. 23 Additionally, a phase I single-dose study conducted in healthy adults has demonstrated pharmacokinetic equivalence of ABP 501 to adalimumab. 24, 38, 39 Data from the present study indicate that ABP 501 and adalimumab have similar clinical efficacy, safety and immunogenicity profiles over 52 weeks of treatment in a sensitive population of immunocompetent patients with moderate-to-severe psoriasis. A single transition from adalimumab to ABP 501 at week 16 had no impact on the efficacy, safety or immunogenicity results for the remainder of the study. In a separate clinical trial that included patients with moderate-to-severe rheumatoid arthritis, ABP 501 and adalimumab have also been shown to be similar with respect to efficacy, safety and immunogenicity. 25 Together these data contribute to the totality-of-evidence- based requirements of showing overall similarity between the proposed biosimilar ABP 501 and its originator adalimumab.
